Clinical Trial

Incretin Microdosing for Cardiometabolic Health in People With HIV

Study acronym: REINFORCE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objectives of this study are as follows: Primary Objective * To determine the rate of weight regain in people living with human immunodeficiency virus (HIV) (PWH) receiving semaglutide microdosing vs. no additional drug following induction therapy. Secondary Objectives * To evaluate the tolerability of semaglutide microdosing in adults with HIV. * To evaluate changes in weight, waist circumference (WC) and body mass index (BMI) over 12 weeks (W) of semaglutide weight loss induction and 48 W of semaglutide microdosing therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2026-02-13
Trial Details
NCT Number NCT07325500
Lead Sponsor The University of Texas Health Science Center, Houston
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Colorado Denver - Anschutz Medical Campus (UCD-AMC), Massachusetts General Hospital (MGH)
Conditions Weight Gain
Enrollment 30 participants
Start Date 2026-02-12
Primary Completion 2028-05-31 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-18